Risk in CNS Drug Discovery: Focus on Alzheimer's Disease
Author Information
Author(s): Pritchard J Fred
Primary Institution: MDS Pharma Services
Hypothesis
How can risk in drug discovery and development for Alzheimer's disease be effectively managed?
Conclusion
Effective risk management in drug discovery can lead to better therapies for neurodegenerative diseases like Alzheimer's.
Supporting Evidence
- Only about 8% of CNS drugs make it to the US market.
- Research and development spending has increased threefold since 1993, but new drug approvals have decreased.
- Modern drug discovery techniques can reduce the risk of failure in clinical trials.
Takeaway
Making new medicines is really hard, especially for brain diseases like Alzheimer's. We need to be smart about choosing the right drugs and planning carefully to help people better.
Methodology
The paper discusses risk management strategies in drug discovery, focusing on stakeholder perspectives and decision-making processes.
Potential Biases
Potential conflicts of interest due to the author's employment in the pharmaceutical industry.
Limitations
The paper does not provide specific data or case studies to support its claims.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website